Itoh H, Nakao K, Mukoyama M, Saito Y, Yamada T, Shirakami G, Arai H, Hosoda K, Suga S, Yoshida I
Department of Medicine, Kyoto University School of Medicine, Japan.
Endocrinology. 1990 Sep;127(3):1292-300. doi: 10.1210/endo-127-3-1292.
Two monoclonal antibodies (mAbs) directed toward brain natriuretic peptide (BNP), KY-BNP-I and KY-BNP-II, have been produced. Both mAbs against BNP possessed high affinities for BNP, with association constants (Ka) of 4.0 X 10(9) M-1 (KY-BNP-I) and 2.0 X 10(10) M-1 (KY-BNP-II). With these mAbs, specific RIAs for BNP have been established. The least detectable quantities of BNP were 5 pg/tube (KY-BNP-I) and 1 pg/tube (KY-BNP-II). Cross-reactivities of alpha-human and rat atrial natriuretic polypeptides were less than 0.001%. These RIAs detected BNP-like immunoreactivity (BNP-LI) not only in the porcine brain but also in the canine brain, with the highest concentration in the medulla oblongata. These RIAs also detected BNP-LI in both the porcine and canine hearts and in the porcine plasma. The iv pretreatment of purified mAb[KY-BNP-II] almost completely blocked the hypotensive action of iv administered BNP in rats, with the concomitant suppression of BNP-induced increase of the plasma cyclic GMP level. These results indicate that our mAbs against BNP will serve as a useful tool for the elucidation of the physiological and pathophysiological significance of BNP as a neuropeptide and as a hormone.